Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Cervical Cancer

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 82 articles:
HTML format
Text format



Single Articles


    May 2018
  1. OLORUNFEMI G, Ndlovu N, Masukume G, Chikandiwa A, et al
    Temporal trends in the epidemiology of cervical cancer in South Africa (1994-2012).
    Int J Cancer. 2018 May 22. doi: 10.1002/ijc.31610.
    PubMed     Text format     Abstract available


    April 2018
  2. DE STROOPER LMA, Berkhof J, Steenbergen RDM, Lissenberg-Witte BI, et al
    Cervical cancer risk in HPV-positive women after a negative FAM19A4/mir124-2 methylation test: A post hoc analysis in the POBASCAM trial with 14 year follow-up.
    Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31539.
    PubMed     Text format     Abstract available


    March 2018
  3. KELLEN E, Benoy I, Vanden Broeck D, Martens P, et al
    A randomized, controlled trial of two strategies of offering the home-based HPV self-sampling test to non- participants in the Flemish cervical cancer screening program.
    Int J Cancer. 2018 Mar 23. doi: 10.1002/ijc.31391.
    PubMed     Text format     Abstract available


  4. YU L, Jiang M, Qu P, Wu Z, et al
    Clinical Evaluation of Human Papillomavirus 16/18 Oncoprotein Test for Cervical Cancer Screening and HPV Positive Women Triage.
    Int J Cancer. 2018 Mar 9. doi: 10.1002/ijc.31368.
    PubMed     Text format     Abstract available


    February 2018
  5. LECAVALIER-BARSOUM M, Chaudary N, Han K, Koritzinsky M, et al
    Targeting the CXCL12/CXCR4 Pathway and Myeloid Cells to Improve Radiation Treatment of Locally Advanced Cervical Cancer.
    Int J Cancer. 2018 Feb 8. doi: 10.1002/ijc.31297.
    PubMed     Text format     Abstract available


    January 2018
  6. DE KOK IMCM, Korfage IJ, van den Hout WB, Helmerhorst TJM, et al
    Quality of life assumptions determine which cervical cancer screening strategies are cost-effective.
    Int J Cancer. 2018 Jan 19. doi: 10.1002/ijc.31265.
    PubMed     Text format     Abstract available


  7. BASU P, Ponti A, Anttila A, Ronco G, et al
    Status of implementation and organization of cancer screening in The European Union Member States-Summary results from the second European screening report.
    Int J Cancer. 2018;142:44-56.
    PubMed     Text format     Abstract available


    December 2017
  8. GULTEKIN M, Zayifoglu Karaca M, Kucukyildiz I, Dundar S, et al
    Initial results of population based cervical cancer screening program using hpv testing in one million turkish women.
    Int J Cancer. 2017 Dec 13. doi: 10.1002/ijc.31212.
    PubMed     Text format     Abstract available


  9. SAND FL, Frederiksen K, Munk C, Jensen SM, et al
    Long-Term Risk of Cervical Cancer Following Conization of Cervical Intraepithelial Neoplasia Grade 3 - A Danish Nationwide Cohort Study.
    Int J Cancer. 2017 Dec 8. doi: 10.1002/ijc.31202.
    PubMed     Text format     Abstract available


    October 2017
  10. MATSUZAKI S, Serada S, Hiramatsu K, Nojima S, et al
    Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer.
    Int J Cancer. 2017 Oct 21. doi: 10.1002/ijc.31124.
    PubMed     Text format     Abstract available


  11. MATSUO K, Shimada M, Yamaguchi S, Kanao H, et al
    Identifying a candidate population for ovarian conservation in young women with clinical stage IB-IIB cervical cancer.
    Int J Cancer. 2017 Oct 4. doi: 10.1002/ijc.31084.
    PubMed     Text format     Abstract available


  12. PAN R, Zhu M, Yu C, Lv J, et al
    Cancer incidence and mortality: A cohort study in China, 2008-2013.
    Int J Cancer. 2017;141:1315-1323.
    PubMed     Text format     Abstract available


    September 2017
  13. ZHANG Q, Dong L, Hu S, Feng R, et al
    Risk stratification and long-term risk prediction of E6 oncoprotein in a prospective screening cohort in China.
    Int J Cancer. 2017;141:1110-1119.
    PubMed     Text format     Abstract available


    August 2017
  14. CLARKE MA, Luhn P, Gage JC, Bodelon C, et al
    Discovery and validation of candidate host DNA methylation markers for detection of cervical precancer and cancer.
    Int J Cancer. 2017;141:701-710.
    PubMed     Text format     Abstract available


  15. CHASIMPHA SJD, Parkin DM, Masamba L, Dzamalala CP, et al
    Three-year cancer incidence in Blantyre, Malawi (2008-2010).
    Int J Cancer. 2017;141:694-700.
    PubMed     Text format     Abstract available


  16. VELENTZIS LS, Caruana M, Simms KT, Lew JB, et al
    How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccina
    Int J Cancer. 2017 Aug 12. doi: 10.1002/ijc.30926.
    PubMed     Text format     Abstract available


    July 2017
  17. VACCARELLA S, Laversanne M, Ferlay J, Bray F, et al
    Cervical cancer in Africa, Latin America and the Caribbean, and Asia: Regional inequalities and changing trends.
    Int J Cancer. 2017 Jul 22. doi: 10.1002/ijc.30901.
    PubMed     Text format     Abstract available


  18. KHAN S, Oosterhuis K, Wunderlich K, Bunnik EM, et al
    Development of a replication-deficient adenoviral vector-based vaccine candidate for the interception of HPV16- and HPV18-induced infections and disease.
    Int J Cancer. 2017;141:393-404.
    PubMed     Text format     Abstract available


  19. BROTHERTON JM, Tabrizi SN, Phillips S, Pyman J, et al
    Looking beyond human papillomavirus (HPV) genotype 16 and 18: Defining HPV genotype distribution in cervical cancers in Australia prior to vaccination.
    Int J Cancer. 2017 Jul 5. doi: 10.1002/ijc.30871.
    PubMed     Text format     Abstract available


  20. MASSAD LS, Hessol NA, Darragh TM, Minkoff H, et al
    Cervical cancer incidence after up to 20 years of observation among women with HIV.
    Int J Cancer. 2017 Jul 3. doi: 10.1002/ijc.30866.
    PubMed     Text format     Abstract available


  21. VELDHUIJZEN NJ, Polman NJ, Snijders PJF, Meijer CJLM, et al
    Stratifying HPV-positive women for CIN3+ risk after one and two rounds of HPV-based screening.
    Int J Cancer. 2017 Jul 3. doi: 10.1002/ijc.30865.
    PubMed     Text format     Abstract available


    June 2017
  22. MATSUMOTO K, Yaegashi N, Iwata T, Yamamoto K, et al
    Early impact of the Japanese immunization program implemented before the HPV vaccination crisis.
    Int J Cancer. 2017 Jun 28. doi: 10.1002/ijc.30855.
    PubMed     Text format    


    May 2017
  23. MATSUO K, Shimada M, Aoki Y, Sakamoto M, et al
    Comparison of adjuvant therapy for node-positive clinical stage IB-IIB cervical cancer: Systemic chemotherapy versus pelvic irradiation.
    Int J Cancer. 2017 May 19. doi: 10.1002/ijc.30793.
    PubMed     Text format     Abstract available


  24. LAM JU, Rebolj M, Moller Ejegod D, Pedersen H, et al
    Human papillomavirus self-sampling for screening nonattenders: Opt-in pilot implementation with electronic communication platforms.
    Int J Cancer. 2017;140:2212-2219.
    PubMed     Text format     Abstract available


  25. AGORASTOS T, Chatzistamatiou K, Moysiadis T, Kaufmann AM, et al
    Human papillomavirus E7 protein detection as a method of triage to colposcopy of HPV positive women, in comparison to genotyping and cytology. Final results of the PIPAVIR study.
    Int J Cancer. 2017 May 3. doi: 10.1002/ijc.30761.
    PubMed     Text format    


  26. SHEN C, Liu Y, Shi S, Zhang R, et al
    Long-distance interaction of the integrated HPV fragment with MYC gene and 8q24.22 region up-regulating the allele-specific MYC expression in HeLa cells.
    Int J Cancer. 2017 May 3. doi: 10.1002/ijc.30763.
    PubMed     Text format     Abstract available


  27. NICOLAS-PARRAGA S, Alemany L, de Sanjose S, Bosch FX, et al
    Differential HPV16 variant distribution in squamous cell carcinoma, adenocarcinoma and adenosquamous cell carcinoma.
    Int J Cancer. 2017;140:2092-2100.
    PubMed     Text format     Abstract available


    April 2017
  28. ROHNER E, Sengayi M, Goeieman B, Michelow P, et al
    Cervical Cancer Risk and Impact of Pap-based Screening in HIV-positive Women on Antiretroviral Therapy in Johannesburg, South Africa.
    Int J Cancer. 2017 Apr 25. doi: 10.1002/ijc.30749.
    PubMed     Text format     Abstract available


  29. BALTZER N, Sundstrom K, Nygard JF, Dillner J, et al
    Risk Stratification in Cervical Cancer Screening by Complete Screening History- Applying Bioinformatics to a General Screening Population.
    Int J Cancer. 2017 Apr 6. doi: 10.1002/ijc.30725.
    PubMed     Text format     Abstract available


  30. DE MARTEL C, Plummer M, Vignat J, Franceschi S, et al
    Worldwide burden of cancer attributable to HPV by site, country and HPV type.
    Int J Cancer. 2017 Apr 1. doi: 10.1002/ijc.30716.
    PubMed     Text format     Abstract available


    March 2017
  31. MEZEI AK, Armstrong HL, Pedersen HN, Campos NG, et al
    Cost-effectiveness of cervical cancer screening methods in low- and middle-income countries: a systematic review.
    Int J Cancer. 2017 Mar 15. doi: 10.1002/ijc.30695.
    PubMed     Text format     Abstract available


  32. HO D, Drake TK, Smith-McCune KK, Darragh TM, et al
    Feasibility of clinical detection of cervical dysplasia using angle-resolved low coherence interferometry measurements of depth-resolved nuclear morphology.
    Int J Cancer. 2017;140:1447-1456.
    PubMed     Text format     Abstract available


  33. DAS GHOSH D, Mukhopadhyay I, Bhattacharya A, Roy Chowdhury R, et al
    Impact of genetic variations and transcriptional alterations of HLA class I genes on cervical cancer pathogenesis.
    Int J Cancer. 2017 Mar 7. doi: 10.1002/ijc.30681.
    PubMed     Text format     Abstract available


    January 2017
  34. RODRIGUEZ AC, Avila C, Herrero R, Hildesheim A, et al
    Cervical cancer incidence after screening with HPV, cytology, and visual methods: 18-year follow-up of the Guanacaste cohort.
    Int J Cancer. 2017 Jan 24. doi: 10.1002/ijc.30614.
    PubMed     Text format     Abstract available


  35. POLMAN NJ, Uijterwaal MH, Witte BI, Berkhof J, et al
    Good performance of p16/ki-67 dual-stained cytology for surveillance of women treated for high-grade CIN.
    Int J Cancer. 2017;140:423-430.
    PubMed     Text format     Abstract available


  36. MANCINI S, Ravaioli A, Giuliani O, Vattiato R, et al
    Incidence and survival trends of cervical adenocarcinoma in Italy: Cytology screening has become more effective in downstaging the disease but not in detecting its precursors.
    Int J Cancer. 2017;140:247-248.
    PubMed     Text format    


    December 2016
  37. CHEN W, Molijn A, Enqi W, Zhang X, et al
    The variable clinicopathological categories and role of human papillomavirus in cervical adenocarcinoma: A hospital based nation-wide multi-center retrospective study across China.
    Int J Cancer. 2016;139:2687-2697.
    PubMed     Text format     Abstract available


  38. CAMPOS NG, Tsu V, Jeronimo J, Mvundura M, et al
    To Expand Coverage, or Increase Frequency: Quantifying the Tradeoffs between Equity and Efficiency Facing Cervical Cancer Screening Programs in Low-Resource Settings.
    Int J Cancer. 2016 Dec 7. doi: 10.1002/ijc.30551.
    PubMed     Text format     Abstract available


    November 2016
  39. KOCSIS A, Takacs T, Jeney C, Schaff Z, et al
    Performance of a New HPV and Biomarker Assay in Management of hrHPV Positive Women: Subanalysis of the Ongoing Multicenter TRACE Clinical Trial (n>6,000) to Evaluate POU4F3 as a Potential Biomarker of Cervical Precancer and Cancer.
    Int J Cancer. 2016 Nov 22. doi: 10.1002/ijc.30534.
    PubMed     Text format     Abstract available


  40. HABBEMA D, Weinmann S, Arbyn M, Kamineni A, et al
    Harms of Cervical Cancer Screening in the United States and the Netherlands.
    Int J Cancer. 2016 Nov 16. doi: 10.1002/ijc.30524.
    PubMed     Text format     Abstract available


    October 2016
  41. WU S, Wang S, Fu Y, Tang W, et al
    A novel mechanism of rs763110 polymorphism contributing to cervical cancer risk by affecting the binding affinity of CEBP/beta and OCT1 complex to chromatin.
    Int J Cancer. 2016 Oct 28. doi: 10.1002/ijc.30490.
    PubMed     Text format     Abstract available


  42. HOLT HK, Zhang L, Zhao FH, Hu SY, et al
    Evaluation of multiple primary and combination screening strategies in postmenopausal women for detection of cervical cancer in China.
    Int J Cancer. 2016 Oct 11. doi: 10.1002/ijc.30468.
    PubMed     Text format     Abstract available


  43. SCHIFFMAN M, Yu K, Zuna R, Terence Dunn S, et al
    Proof-of-principle study of a novel cervical screening and triage strategy: computer-analyzed cytology to decide which HPV-positive women are likely to have >/=CIN2.
    Int J Cancer. 2016 Oct 1. doi: 10.1002/ijc.30456.
    PubMed     Text format     Abstract available


    September 2016
  44. OGILVIE GS, Krajden M, van Niekerk D, Smith LW, et al
    HPV For Cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid based cytology for cervical cancer.
    Int J Cancer. 2016 Sep 29. doi: 10.1002/ijc.30454.
    PubMed     Text format     Abstract available


  45. CASTANON A, Landy R, Sasieni PD
    Is cervical screening preventing adenocarcinoma and adenosquamous carcinoma of the cervix?
    Int J Cancer. 2016;139:1040-5.
    PubMed     Text format     Abstract available


    August 2016
  46. SIMMS KT, Smith MA, Lew JB, Kitchener HC, et al
    Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries.
    Int J Cancer. 2016 Aug 19. doi: 10.1002/ijc.30392.
    PubMed     Text format     Abstract available


  47. ISIDEAN SD, Mayrand MH, Ramanakumar AV, Gilbert L, et al
    Human Papillomavirus Testing versus Cytology in Primary Cervical Cancer Screening: End-of-Study and Extended Follow-Up Results from the Canadian Cervical Cancer Screening Trial (CCCaST).
    Int J Cancer. 2016 Aug 18. doi: 10.1002/ijc.30385.
    PubMed     Text format     Abstract available


  48. CAMPBELL C, Kafwafwa S, Brown H, Walker G, et al
    Use of thermo-coagulation as an alternative treatment modality in a 'screen-and-treat' programme of cervical screening in rural Malawi.
    Int J Cancer. 2016;139:908-15.
    PubMed     Text format     Abstract available


  49. SCHIFFMAN M, Hyun N, Raine-Bennett TR, Katki H, et al
    A Cohort Study of Cervical Screening Using Partial HPV Typing and Cytology Triage.
    Int J Cancer. 2016 Aug 10. doi: 10.1002/ijc.30375.
    PubMed     Text format     Abstract available


    June 2016
  50. DEPUYDT CE, Thys S, Beert J, Jonckheere J, et al
    Linear viral load increase of a single HPV-type in women with multiple HPV infections predicts progression to cervical cancer.
    Int J Cancer. 2016 Jun 24. doi: 10.1002/ijc.30238.
    PubMed     Text format     Abstract available


  51. ZHAO FH, Hu SY, Zhang Q, Zhang X, et al
    Risk assessment to guide cervical screening strategies in a large Chinese population.
    Int J Cancer. 2016;138:2639-47.
    PubMed     Text format     Abstract available


    May 2016
  52. CARLANDER C, Wagner P, Svedhem V, Elfgren K, et al
    Impact of immunosuppression and region of birth on risk of cervical intraepithelial neoplasia among migrants living with HIV in Sweden.
    Int J Cancer. 2016 May 13. doi: 10.1002/ijc.30188.
    PubMed     Text format     Abstract available


    April 2016
  53. TANG A, Dadaglio G, Oberkampf M, Di Carlo S, et al
    B cells promote tumor progression in a mouse model of HPV-mediated cervical cancer.
    Int J Cancer. 2016 Apr 30. doi: 10.1002/ijc.30169.
    PubMed     Text format     Abstract available


  54. RADDE K, Gottschalk A, Bussas U, Schulein S, et al
    Invitation to cervical cancer screening does increase participation in Germany: Results from the MARZY Study.
    Int J Cancer. 2016 Apr 15. doi: 10.1002/ijc.30146.
    PubMed     Text format     Abstract available


    March 2016
  55. EBISCH RM, de Kuyper-de Ridder GM, Bosgraaf RP, Massuger LF, et al
    The clinical value of HPV genotyping in triage of women with high-risk-HPV-positive self-samples.
    Int J Cancer. 2016 Mar 17. doi: 10.1002/ijc.30090.
    PubMed     Text format     Abstract available


    February 2016
  56. BROTHERTON JM, Jit M, Gravitt PE, Brisson M, et al
    Eurogin Roadmap 2015: How has HPV knowledge changed our practice: vaccines.
    Int J Cancer. 2016 Feb 24. doi: 10.1002/ijc.30063.
    PubMed     Text format     Abstract available


  57. HERWEIJER E, Sundstrom K, Ploner A, Uhnoo I, et al
    Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: A population-based study.
    Int J Cancer. 2016 Feb 9. doi: 10.1002/ijc.30035.
    PubMed     Text format     Abstract available


  58. PETRY KU, Cox JT, Johnson K, Quint W, et al
    Evaluating HPV negative CIN2+ in the ATHENA trial.
    Int J Cancer. 2016 Feb 6. doi: 10.1002/ijc.30032.
    PubMed     Text format     Abstract available


  59. BHATIA R, Kavanagh K, Cubie H, Serrano I, et al
    Use of HPV testing for cervical screening in vaccinated women - insights from the SHEVa (Scottish HPV Prevalence in Vaccinated Women) study.
    Int J Cancer. 2016 Feb 4. doi: 10.1002/ijc.30030.
    PubMed     Text format     Abstract available


    January 2016
  60. MOLIJN A, Jenkins D, Chen W, Zhang X, et al
    The complex relationship between human papillomavirus and cervical adenocarcinoma.
    Int J Cancer. 2016;138:409-16.
    PubMed     Text format     Abstract available


  61. STENSEN S, Kjaer SK, Jensen SM, Frederiksen K, et al
    Factors associated with type-specific persistence of high-risk human papillomavirus infection: A population-based study.
    Int J Cancer. 2016;138:361-8.
    PubMed     Text format     Abstract available


  62. VAN BAARS R, van der Marel J, Snijders PJ, Rodriquez-Manfredi A, et al
    CADM1 and MAL methylation status in cervical scrapes is representative of the most severe underlying lesion in women with multiple cervical biopsies.
    Int J Cancer. 2016;138:463-71.
    PubMed     Text format     Abstract available


  63. SHEPPARD C, El-Zein M, Ramanakumar AV, Ferenczy A, et al
    Assessment of mediators of racial disparities in cervical cancer survival in the United States.
    Int J Cancer. 2016 Jan 12. doi: 10.1002/ijc.29996.
    PubMed     Text format     Abstract available


    December 2015
  64. SKINNER SR, Wheeler CM, Romanowski B, Castellsague X, et al
    Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study.
    Int J Cancer. 2015 Dec 19. doi: 10.1002/ijc.29971.
    PubMed     Text format     Abstract available


  65. HOLL K, Nowakowski AM, Powell N, McCluggage WG, et al
    Human papillomavirus prevalence and type-distribution in cervical glandular neoplasias: Results from a European multinational epidemiological study.
    Int J Cancer. 2015;137:2858-68.
    PubMed     Text format     Abstract available


  66. HAMMER A, Rositch A, Qeadan F, Gravitt PE, et al
    Age-specific prevalence of HPV16/18 genotypes in cervical cancer: a systematic review and meta-analysis.
    Int J Cancer. 2015 Dec 13. doi: 10.1002/ijc.29959.
    PubMed     Text format     Abstract available


    November 2015
  67. CLIFFORD GM, Franceschi S, Keiser O, Schoni-Affolter F, et al
    Immunodeficiency and the risk of cervical intra-epithelial neoplasia 2/3 and cervical cancer: A nested case-control study in the Swiss HIV Cohort Study.
    Int J Cancer. 2015 Nov 4. doi: 10.1002/ijc.29913.
    PubMed     Text format     Abstract available


    September 2015
  68. VALDEZ M, Jeronimo J, Bansil P, Qiao YL, et al
    Effectiveness of novel, lower-cost molecular human papillomavirus-based tests for cervical cancer screening in rural China.
    Int J Cancer. 2015 Sep 30. doi: 10.1002/ijc.29877.
    PubMed     Text format     Abstract available


  69. ZHANG R, Shen C, Zhao L, Wang J, et al
    Dysregulation of host cellular genes targeted by HPV integration contributes to HPV related cervical carcinogenesis.
    Int J Cancer. 2015 Sep 29. doi: 10.1002/ijc.29872.
    PubMed     Text format     Abstract available


    August 2015
  70. LUTTMER R, De Strooper LM, Berkhof J, Snijders PJ, et al
    Comparing the performance of FAM19A4 methylation analysis, cytology and HPV16/18 genotyping for the detection of cervical (pre)cancer in high-risk HPV-positive women of a gynecologic outpatient population (COMETH study).
    Int J Cancer. 2015 Aug 28. doi: 10.1002/ijc.29824.
    PubMed     Text format     Abstract available


  71. CHUNG TK, Van Hummelen P, Chan PK, Cheung TH, et al
    Genomic aberrations in cervical adenocarcinomas in Hong Kong Chinese women.
    Int J Cancer. 2015;137:776-83.
    PubMed     Text format     Abstract available


    July 2015
  72. VACCARELLA S, Franceschi S, Bray F
    The incremental benefits of implementing effective cervical cancer screening.
    Int J Cancer. 2015 Jul 23. doi: 10.1002/ijc.29700.
    PubMed     Text format    


  73. HEIDENREICH R, Jasny E, Kowalczyk A, Lutz J, et al
    A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile.
    Int J Cancer. 2015;137:372-84.
    PubMed     Text format     Abstract available


  74. THOMSEN LT, Frederiksen K, Munk C, Junge J, et al
    Long-term risk of cervical intraepithelial neoplasia grade 3 or worse according to high-risk human papillomavirus genotype and semi-quantitative viral load among 33,288 women with normal cervical cytology.
    Int J Cancer. 2015;137:193-203.
    PubMed     Text format     Abstract available


    June 2015
  75. ANTILL YC, Dowty JG, Ko Win A, Thompson T, et al
    Lynch Syndrome and Cervical Cancer.
    Int J Cancer. 2015 Jun 15. doi: 10.1002/ijc.29641.
    PubMed     Text format     Abstract available


  76. CUZICK J, Myers O, Hunt WC, Saslow D, et al
    Human papillomavirus testing 2007-2012: co-testing and triage utilization and impact on subsequent clinical management.
    Int J Cancer. 2015;136:2854-63.
    PubMed     Text format     Abstract available


  77. NAKAJIMA A, Endo H, Okuyama H, Kiyohara Y, et al
    Radiation sensitivity assay with a panel of patient-derived spheroids of small cell carcinoma of the cervix.
    Int J Cancer. 2015;136:2949-60.
    PubMed     Text format     Abstract available


  78. NGOMA T, Mandeli J, Holland JF
    Downstaging cancer in rural Africa.
    Int J Cancer. 2015;136:2875-9.
    PubMed     Text format     Abstract available


    May 2015
  79. HE Y, Lin J, Ding Y, Liu G, et al
    A systematic study on dysregulated microRNAs in cervical cancer development.
    Int J Cancer. 2015 May 27. doi: 10.1002/ijc.29618.
    PubMed     Text format     Abstract available


    March 2015
  80. OGILVIE GS, Naus M, Money DM, Dobson SR, et al
    Reduction in cervical dysplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis.
    Int J Cancer. 2015 Mar 6. doi: 10.1002/ijc.29508.
    PubMed     Text format     Abstract available


    January 2015
  81. VERDOODT F, Jiang X, Williams M, Schnatz PF, et al
    High-risk HPV testing in the management of atypical glandular cells: a systematic review and meta-analysis.
    Int J Cancer. 2015 Jan 12. doi: 10.1002/ijc.29424.
    PubMed     Text format     Abstract available


    October 2014
  82. UIJTERWAAL MH, Polman N, Witte BI, vanKemenade FJ, et al
    Full title: Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: Baseline and longitudinal data.
    Int J Cancer. 2014 Oct 25. doi: 10.1002/ijc.29290.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Cervical Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: